PBYI
HealthcarePuma Biotechnology, Inc.
$5.94
+$0.17 (+2.95%)
Jan 5, 2026
Price History (1Y)
Analysis
Puma Biotechnology, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $299.32M and 172 employees. The company's revenue and employee count are relatively small compared to its peers. The company's financial health indicates profitability with gross margin at 76.9%, operating margin at 17.6%, and profit margin at 17.4%. Puma Biotechnology also demonstrates strong returns on equity (39.7%) and assets (9.9%). However, the company's balance sheet shows debt ($41.05M) that is a significant portion of its market capitalization. Puma Biotechnology's valuation metrics include a P/E ratio (TTM) of 7.82, forward P/E of 10.80, and price to book of 2.60. The company has experienced negative growth in revenue (-32.4% YoY) and earnings (-58.5% YoY).
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Visit website →Key Statistics
- Market Cap
- $299.32M
- P/E Ratio
- 7.82
- 52-Week High
- $6.27
- 52-Week Low
- $2.58
- Avg Volume
- 485.02K
- Beta
- 1.18
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 172